Needham & Company Upgrades Zimmer Biomet (ZBH) to Strong Buy
Needham & Company analyst Mike Matson upgraded Zimmer Biomet (NYSE: ZBH) from Buy to Strong Buy with a price target ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
